1370339-88-0

Basic information

• Product Name: [3-(3,4-bis-benzyloxy-phenyl)propyl](2-n-butyl-5-chloro-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl)amine
• Synonyms: [3-(3,4-bis-benzyloxy-phenyl)propyl](2-n-butyl-5-chloro-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl)amine
• CAS NO: 1370339-88-0
• Molecular Weight: 994.679
• Mol File: 1370339-88-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [3-(3,4-bis-benzyloxy-phenyl)propyl](2-n-butyl-5-chloro-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl)amine(CAS DataBase Reference)
• NIST Chemistry Reference: [3-(3,4-bis-benzyloxy-phenyl)propyl](2-n-butyl-5-chloro-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl)amine(1370339-88-0)
• EPA Substance Registry System: [3-(3,4-bis-benzyloxy-phenyl)propyl](2-n-butyl-5-chloro-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl)amine(1370339-88-0)

Safety Data

• Hazardous Substances Data: 1370339-88-0(Hazardous Substances Data)

Upstream product

• 133910-00-6 2-n-Butyl-4-chloro-1-[(2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imidazole-5-carboxaldehyde 
• 99281-96-6 3-<3,4-bis(benzyloxy)phenyl>-1-aminopropane 

Downstream Products

• 1370339-90-4 4-[3-((2-n-butyl-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl)amino)propyl]benzene-1,2-diol 
• 1370339-89-1 4-[3-((2-n-butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl)amino)propyl]benzene-1,2-diol 

Relevant articles and documents

New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers

We report new examples of a series of losartan-hydrocaffeic hybrids that bear novel ester, amide and amine linkers. These compounds were made by linking hydrocaffeic acid to the side chain of losartan at the C-5 position of the imidazole ring through different strategies. Experiments performed in cultured cells demonstrate that these new hybrids retain the ability to block the angiotensin II effect and have increased antioxidant ability. Most of them reduced arterial pressure in rats better or as much as losartan.